Research programme: cardiovascular disease therapeutics - Biostar Pharmaceuticals/Northwest University
Latest Information Update: 28 Jan 2019
At a glance
- Originator BioStar Pharmaceuticals; Northwest University
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for research development in Cardiovascular-disorders in China
- 08 Jan 2015 Northwest University has patent protection for Danshensu Yibingzhi in China
- 08 Jan 2015 Department of Education and Finance, Shaanxi Province, China approved Danshensu Yibingzhi for further industrial and commercial development